Zoster Eye Disease Study (ZEDS): A multicenter, randomized trial of valacyclovir in patients with Herpes Zoster Ophthalmicus (HZO)

S
Shaohui Liu, MD

Primary Investigator

Overview

To evaluate whether or not prolonged suppressive oral antiviral treatment with valacyclovir reduces complications of HZO including new or worsening dendriform epithelial keratitis, stromal keratitis, endothelial keratitis, and/or iritis and/or postherpetic neuralgia compared to placebo.

Description

Study location can be either the Glick Eye Institute on the IUPUI campus, or at the Glick Eye Institute Springmill, which is located on N. Illinois St.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    eye,eyes,vision,herpes zoster ophthalmicus,HZO,dendriform epithelial keratitis,stromal keratitis,endothelial keratitis,iritis,postherpetic neuralgia,1903188647
  • Age: Between 18 Years - 100 Years
  • Gender: All

Eligibility Criteria
Diagnosis of HZO in one eye
 
Exclusion Criteria
Diagnosis of Leukemia, Lymphoma
Treatment with chemotherapy within the last 3 months
 
Additional Information:

Updated on 23 Aug 2023. Study ID: 1903188647

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center